18 results about "Organ dysfunction" patented technology

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

The present invention relates to metal nanoparticles and a plasmonic biosensor including the same. According to the present invention, it is possible to provide novel metal nanoparticles having significantly improved sensitivity to light, and further, it is possible to provide a plasmonic biosensor capable of detecting a trace amount of a biomarker present in a biological sample with high precision through the metal nanoparticles. In addition, the plasmonic biosensor is capable of detecting a sepsis biomarker with high sensitivity and specificity, and thus may be usefully used in various clinical applications such as sepsis diagnosis, identification of the type of organ dysfunction, prediction of sepsis severity, and post-treatment.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute lung injury and a preparation method and application thereof. The traditional Chinese medicine composition for treating the acute lung injury is prepared from the following raw materials in parts by weight: 10 to 15 parts of cortex moutan, 15 to 25 parts of radix paeoniae rubra, 25 to 35 parts of radix rehmanniae recen, 10 to 20 parts of semen persicae, 10 to 20 parts of fructus aurantii immaturus, 10 to 15 parts of radix curcumae, 10 to 15 parts of rhizoma acori graminei, 15 to 25 parts of fructus trichosanthis, 10 to 20 parts of fructus forsythiae, 10 to 20 parts of rhizoma polygoni cuspidati, 15 to 25 parts of semen lepidii and 25 to 35 parts of radix astragali seu hedysari. The traditional Chinese medicine composition has the beneficial effects that the traditional Chinese medicine composition for treating the acute lung injury can play a role in the aspects of improving the immune state, improving circulation and the like by influencing the release of inflammatory factors; the traditional Chinese medicine composition can improve the treatment effective rate and off-line success rate of acute lung injury patients, shorten the mechanical ventilation time, improve the oxygenation index of the patients, reduce the expression of proinflammatory factors IL-6, regulate the immune balance of Th1 / Th2 and Th17 / Treg, improve hemagglutination and relieve the disease severity and multi-organ dysfunction of the patients.

The invention discloses a traditional Chinese medicine composition for preventing and treating sepsis microcirculation and blood coagulation dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of ginseng, 5-15 parts of rheum officinale, 20-40 parts of sargentgloryvine stem, 20-40 parts of dandelion, 20-40 parts of radix aconiti carmichaeli and 2-8 parts of leech. The traditional Chinese medicine composition has the effects of supporting the healthy energy, clearing away heat and toxic materials and promoting blood circulation to remove blood stasis, clinical tests show that the traditional Chinese medicine composition can remarkably improve microcirculation disturbance and blood coagulation dysfunction of a sepsis patient, reduce the 28-day full-cause case fatality rate of the patient, improve multi-organ dysfunction and relieve inflammatory response for the yang-deficiency and toxin-stasis type sepsis patient, and has good safety. In addition, the invention further discloses a preparation method and application of the traditional Chinese medicine composition.

The present application belongs to the field of biotechnology and medical technology, and particularly relates to Anapc11 gene / protein for screening drugs for treating hyperuricemia related multi-organ dysfunction. The present application uses Anapc11 gene as a molecular target or a drug action target for screening or preparing drugs for treating multi-organ dysfunction caused by hyperuricemia (including liver injury, testicular dysfunction and intestinal barrier damage). The present application provides a new use of cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, breaks the limitation of existing uric acid lowering drugs only in the metabolic link, and provides a new direction and good application prospect for developing innovative drugs with organ protection effect.

This invention belongs to the field of smart healthcare and digital health technology, providing a method and platform for intelligent monitoring and early warning of health risks for people with chronic diseases. The method includes: collecting physiological indicators, lifestyle habits, and traditional Chinese medicine constitution identification information, and fusing them to generate multi-dimensional time-series data on chronic disease characteristics; constructing and dynamically updating a personal dynamic health model; establishing a three-tiered progressive early warning mechanism of L1-level trend deviation, L2-level organ dysfunction, and L3-level complication risk, clarifying the triggering conditions for each level of early warning; based on the early warning level, calling upon a knowledge base of traditional Chinese and Western medicine intervention rules to generate and push personalized intervention plans; collecting feedback data to optimize the model and evaluate the intervention effect. The platform includes a smart terminal layer, a platform service layer, a model knowledge base, and an application interaction layer, adopting an edge-cloud collaborative architecture to improve monitoring real-time performance. This invention, through multi-dimensional data fusion and hierarchical early warning, can achieve early identification and accurate early warning of chronic disease risks.

The invention relates to the technical field of biological medicine, and particularly discloses application of Chinese yam vesicles in preparation of a medicine for preventing and treating sepsis. The Chinese yam vesicles are extracted from Chinese yam through a gradient ultrasonic centrifugation method; according to the scheme, the cognitive limitation that only the Chinese yam vesicles are used for bone metabolism related diseases in the prior art is broken through, and the Chinese yam vesicles are creatively applied to treatment of sepsis characterized by systemic inflammatory response and multi-organ dysfunction for the first time; moreover, experiments prove that the application can be used for remarkably improving the survival rate of sepsis model mice, effectively relieving pathological injuries of multiple organs such as liver, kidney and lung caused by sepsis, remarkably inhibiting the expression of key inflammatory factors TNF-alpha, IL-6 and IL-1beta in serum, and inhibiting the expression of inflammatory factors such as inflammatory factors TNF-alpha, IL-6 and IL-1beta in serum. Therefore, a definite intervention effect is generated on core pathological links (cytokine storm and organ injury) of sepsis; the scheme of the invention provides a brand-new candidate drug and treatment strategy with natural source advantages for solving the problem of clinical treatment of sepsis.

Methods of preventing and / or treating ischemia, organ dysfunction and / or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction / failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

The application discloses a sepsis organ dysfunction early warning method based on sparse data incremental coding, comprising the following steps: obtaining event sequence data and non-event sequence data of a target object, wherein the event sequence data comprises at least one of clinical diagnosis data, treatment record data and laboratory history detection data, and the non-event sequence data comprises at least past medical history data and target sign data; performing incremental coding on the event sequence data to obtain a sparse mode of the event sequence data; processing the sparse mode, the event sequence data and the non-event sequence data according to a pre-constructed early warning model to obtain a sepsis risk index of the target object; and outputting target early warning information in the case that the sepsis risk index meets preset early warning conditions.

The invention discloses an application of magnesium salvianolic acid B (MLB) in preparation of a medicine for preventing or treating sepsis and related multi-organ dysfunction of the sepsis, and particularly discloses an application of magnesium salvianolic acid B (MLB) in preparation of a medicine for preventing or treating the sepsis and the related multi-organ dysfunction of the sepsis and the related multi-organ dysfunction of the sepsis. Experiments prove that in a sepsis animal model, the MLB can significantly improve the survival rate, relieve multi-organ injury, improve hematological abnormality and organ functions, and relieve iron-dependent injury by stabilizing an antioxidant system. And the MLB is natural in source and high in safety, and has a potential application prospect as a candidate drug for preventing and treating sepsis. The invention provides an effective technical means for preventing or treating sepsis and related multi-organ dysfunction thereof.

Embodiments relate to a method of treating a disease or condition in a subject in need thereof, the method comprising: administering a therapeutic effective amount of a pharmaceutical composition comprising mesenchymal cells and exosomes to the subject; wherein the mesenchymal cells and exosomes are in a ratio of about 1: 2500 to 1: 250000; wherein the mesenchymal cells have a stemness quality more than 90% and viability more than 95%, and the exosomes are free of a cellular contaminant as detected by immunoblotting technique, wherein the cellular contaminant comprises calnexin, and treating said disease or condition.

The present application relates to the use of plasma osteocalcin as a biomarker in the preparation of a diagnostic and / or prognostic product for sepsis in children. The prognostic product uses the measurement of osteocalcin levels on the first day of admission of a child with sepsis to assess the degree of organ dysfunction and the need for organ support in patients with sepsis. The present application discloses the potential of osteocalcin as a modulator of the immune inflammatory response in sepsis and that its level changes can be used as a predictive marker of the diagnosis and clinical outcome of sepsis. This finding provides a new biomarker for the early diagnosis, prognosis evaluation and treatment of sepsis and an important basis for clinical management.

The application belongs to the technical field of biomedicine, and specifically discloses a kind of enabled mesenchymal stem cells, enabled mesenchymal stem cell composition and its application in preparation treatment organ dysfunction drug, and the enabled mesenchymal stem cells are obtained by treating human mesenchymal stem cells with a kind of halogenated salicylic alcohol HEP14, and the enabled mesenchymal stem cell composition includes the enabled mesenchymal stem cells and HEP14 / PLGA microspheres with high HEP14 load and long-acting HEP14 sustained release prepared by using polylactic acid-hydroxyacetic acid copolymer (PLGA) as a carrier.The enabled mesenchymal stem cells of the application have the effects of strengthening mesenchymal stem cell survival viability and stemness, resisting tissue fibrosis, promoting tissue angiogenesis, promoting tissue regeneration and functional recovery;the combined application of the enabled mesenchymal stem cells and HEP14 / PLGA microspheres strengthens the retention and transdifferentiation of the enabled mesenchymal stem cells in the tissue, so the function of the enabled mesenchymal stem cells and the application in the field of regenerative medicine are further strengthened.

The invention belongs to the technical field of animal model construction, and discloses a sepsis model construction method, which comprises: preparing a bacterial liquid, carrying out culture amplification on Escherichia coli, carrying out centrifugal collection, washing with a sterile PBS buffer solution, and re-suspending to obtain the bacterial liquid; constructing a model, performing intraperitoneal injection of the bacterial liquid into piglet bodies, and performing intraperitoneal injection of an isopyknic sterile PBS buffer solution into a control group; and feeding: feeding the piglets subjected to intraperitoneal injection for 48 hours to obtain the sepsis model. The invention provides the method for constructing the sepsis model, and the model constructed by the method is simple to operate, stable in effect and good in repeatability, and can comprehensively simulate the inflammatory response of human sepsis, multi-organ dysfunction, intestinal injury and other core pathological characteristics. And a standardized tool with high clinical prediction value is provided for pathogenesis research and treatment evaluation of sepsis.